Skip to content
TrialScanner

NCT04533347

Tafenoquine in Patients With Mild to Moderate COVID-19

Phase 2CompletedSXTPLead

Registry record

Lead sponsor
60 Degrees Pharmaceuticals LLC
Conditions
COVID 19 Disease
Primary completion
Jun 30, 2022Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT04533347 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT04533347: Tafenoquine in Patients With... | TrialScanner